Denator-led Research Consortium Awarded Funding from the EU EUROSTARS Programme
News Aug 26, 2009
Denator AB announced that the consortium focused on improved sample preparation of blood plasma samples has been ranked 31st out of more than 300 European projects and will receive approximately 300 000 Euros in funding from the EU Eurostars Programme.
Denator will participate as lead partner in the new research consortium that will focus on development and verification of a prototype for blood plasma handling. The project will have a special focus on increasing the potential of biomarker discovery for diagnostics and drug development.
Other partners of the consortium are Sigolis AB in Sweden; the Biomolecular Mass Spectrometry Unit at Leiden University Medical Center, headed by Professor Andre Deelder, the Netherlands and the BioScope group, at Universidade Nova de Lisboa, Portugal. The consortium also includes the involvement of a large pharmaceutical company that will support the project with key customer understanding.
Yuri van der Burgt, Assistant Professor at Leiden University Medical Center, says: “Improved and standardized sample handling is a key issue for the discovery of novel peptide- and protein biomarkers. This project holds the potential of immensely facilitating that process”.
This year, competition between applying projects has been extremely fierce. All projects have been assessed by carefully selected independent technical experts and independent evaluation panel. Based on that assessment, technology and innovation, market and competitiveness factors, projects were then ranked across all industries.
Olof Skod, CEO of Denator, says: “This collaboration project will allow us to continue developing exciting new techniques for stabilization of biological samples which will provide unique insights and a deeper understanding of the human proteome and its role in disease. Our involvement in the consortium enables us to work even more closely with existing as well as new collaborative partners. We are confident that working within such a strong team of innovative actors presents the perfect opportunity for developing breakthrough technology.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE